Verition Fund Management
PCVX icon

Verition Fund Management’s Vaxcyte PCVX Stock Holding History

Verition Fund Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,731
Closed -$726K – 3220
2025
Q4 		$726K Sell
15,731
-26,127
-62% -$1.17M ﹤0.01% 2395
2025
Q3 		$1.51M Sell
41,858
-18,495
-31% -$613K 0.01% 2208
2025
Q2 		$1.96M Sell
60,353
-13,921
-19% -$456K 0.01% 1961
2025
Q1 		$2.8M Buy
74,274
+68,201
+1,123% +$5.45M 0.01% 1332
2024
Q4 		$497K Buy
6,073
+1,798
+42% +$179K ﹤0.01% 2493
2024
Q3 		$489K Buy
+4,275
New +$385K ﹤0.01% 2343

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verition Fund Management's PCVX Position: Q1 2026 in Review

Verition Fund Management sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 15,731 shares — an estimated $726K sold.

Verition Fund Management first reported a position in PCVX in Q3 2024 and held it in 6 quarters. The position peaked at $2.8M in Q1 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Verition Fund Management reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 15,731 Vaxcyte shares in Q1 2026, an estimated $726K.
  • Verition Fund Management first reported a position in Vaxcyte in Q3 2024 and held it in 6 quarters.
  • Verition Fund Management's Vaxcyte position peaked at $2.8M in Q1 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.